SET
protein-codingSET nuclear proto-oncogene, the group of SET complex|INHAT complex
Gene summary
The protein encoded by this gene inhibits acetylation of nucleosomes, especially histone H4, by histone acetylases (HAT). This inhibition is most likely accomplished by masking histone lysines from being acetylated, and the consequence is to silence HAT-dependent transcription. The encoded protein is part of a complex localized to the endoplasmic reticulum but is found in the nucleus and inhibits apoptosis following attack by cytotoxic T lymphocytes. This protein can also enhance DNA replication of the adenovirus genome. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~13.0 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0020847
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0020847
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0020847
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0020847
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0015802
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0001071
Submitter: ClinGen
*SET* encodes a multifunctional protein involved in transcriptional regulation and chromatin remodeling. The relationship between variants in *SET* and autosomal dominant intellectual disability (ID) was first reported in 2018 (Stevens et al., PMID: 29688601; Richardson et al., PMID: 29907757). At least 9 variants (5 frameshift, 1 nonsense, 1 splice, 2 missense) have been reported in 10 individuals, with the majority occurring *de novo* (PMIDs: 25356899, 29688601, 29907757). Affected individuals presented with motor and speech delay, ID and variable additional features, including mild dysmorphic features, microcephaly in two individuals, and autism in one. The gene-disease relationship is further supported by experimental evidence, including interactions with proteins involved in histone modification and encoded by known autosomal dominant ID genes (e.g., *CREBBP, CTCF, EP300, KMT2A, SETBP1, RAC1, TREX1*) (PMID:29749127), and *in vitro* studies indicating *SET* is required for neuronal development (PMIDs: 20800572, 28966118). In summary, *SET* is definitively associated with autosomal dominant intellectual disability. This was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on November 17, 2021 (SOP version 8).
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Musculoskeletal; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to SET variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_003011.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 12 | 12 | ||||
| missense | 5 | 45 | 4 | 54 | ||
| nonsense | 4 | 1 | 5 | |||
| start loss | 1 | 1 | ||||
| frameshift | 13 | 12 | 4 | 1 | 30 | |
| splice donor/acceptor (+/-2bp) | 3 | 1 | 6 | 10 | ||
| Total | 21 | 19 | 55 | 17 | 0 | 112 |
Highest pathogenic variant AF is 0.000002575284
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_003002.2 | 8 | MANE Select | |
| Ensembl | ENSP00000318012.9 | 8 | MANE Select | |
| RefSeq | NP_001116293.1 | 8 | Standard | |
| RefSeq | NP_001234929.1 | 8 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| setb | Danio rerio | Structure: post-vent region Quality: curved abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- NOTCH-Ncore
- Histone Modifications
- granzyme a mediated apoptosis pathway
- Metabolism of RNA
- HuR (ELAVL1) binds and stabilizes mRNA
Biological Process
- DNA replication
- nucleosome assembly
- nucleosome disassembly
- viral process
- negative regulation of phosphoprotein phosphatase activity
Molecular Function
- DNA binding
- protein phosphatase inhibitor activity
- protein binding
- protein phosphatase regulator activity
- histone binding
Cellular Component
- nucleus
- nucleoplasm
- cytoplasm
- endoplasmic reticulum
- lipid droplet
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000372692
- Coding exons
- 8
- Length
- 12977
- Individuals with no LoFs
- 0
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 0
- Defined
- 0
- p
- 0.00
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.66 | 55 | 145 | 0.379 | 0.00000706 | 1935 |
| Missense (PolyPhen) | 1 | 25.35 | 0.039448 | 446 | ||
| Synonymous | -0.598 | 60 | 54.4 | 1.10 | 0.00000304 | 471 |
| Loss of Function | 3.74 | 0 | 16.3 | 0.00 | 6.88e-7 | 220 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0 | 0.0 | absent |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T- lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher. {ECO:0000269|PubMed:11555662, ECO:0000269|PubMed:12628186}.;
- Disease
- DISEASE: Note=A chromosomal aberration involving SET is found in some cases of acute undifferentiated leukemia (AUL). Translocation t(6;9)(q21;q34.1) with NUP214/CAN.;
Recessive Scores
- pRec
- 0.296
Intolerance Scores
- LoFtool
- 0.435
- RVIS EVS
- 0.3
- RVIS percentile EVS
- 72.01
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.993
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |